MAIA Biotechnology Ends ATM Stock Offering Agreement

MAIA Biotechnology, Inc. ( (MAIA) ) has issued an announcement.

On May 14, 2026, MAIA Biotechnology, Inc. suspended sales of its common stock under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC and notified the agent that the agreement would be terminated seven business days later, in line with its terms. Since the March 28, 2025 prospectus supplement authorizing up to $11.2 million of stock sales, the company has issued 3,116,012 shares of common stock for gross proceeds of about $5.68 million under the program, signaling the end of this particular capital-raising channel and potentially shifting how MAIA funds its operations going forward.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a company operating in the biotechnology sector. Its primary business centers on the development and commercialization of biopharmaceutical products, with a focus on advancing innovative therapies in its chosen market segments.

Average Trading Volume: 875,306

Technical Sentiment Signal: Sell

Current Market Cap: $79.65M

See more insights into MAIA stock on TipRanks’ Stock Analysis page.